Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers ...

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...

CAR-T therapy is a highly specialized treatment that requires careful patient selection and close monitoring. Some patients ...

Target selection leverages DLL3’s high tumor-surface expression in SCLC/LCNEC and limited normal-tissue expression, while dnTGFBR2 “armoring” aims to blunt TGF-β–mediated T-cell suppression. Dose ...

Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing ...

The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products ...

Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...

Researchers say approach could be useful for both initial treatment of bladder cancer as well as treatment refractory subsets of tumors.